Compare Taskus Inc (TASK) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Taskus Inc vs Zoetis Inc — how do they compare? Taskus Inc trades at $7.05 (market cap $650.52M), while Zoetis Inc trades at $74.92 (market cap $30.92B). The key difference: Zoetis Inc is far larger — about 47.5× Taskus Inc's market cap, and Zoetis Inc pays a 2.83% dividend while Taskus Inc pays none. Which is the better fit depends on your goals.
| TASK | ZTS | |
|---|---|---|
Market Cap | $650.52M | $30.92B |
Sector | Technology | Health |
52-Week High | $18.21 | $156.76 |
52-Week Low | $4.57 | $71.91 |
Enterprise Value | $1.02B | $38.49B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TaskUs (TASK) trades at $7.30, down 6.65% today, but maintains strong fundamentals with Q2 2026 revenue beating guidance by $10.9 million. The stock shows bullish technical signals with support at $7 and bullish moving averages. Valuation metrics appear attractive with P/E of 6.29 and P/S of 0.55, while profitability remains solid with 8.75% net margin and 25.43% ROE. Recent CFO appointment and AI services growth provide positive catalysts.
The outlook remains positive with analyst consensus favoring Buy ratings (54.55%) and improving cash flow trends. Key opportunities include undervaluation relative to earnings power and AI services expansion. Risks include client concentration and potential earnings volatility. The combination of reasonable valuation and growth momentum supports a constructive view for patient investors.
Zoetis (ZTS) trades at $72.66, down 5.92% amid a bearish technical signal and recent earnings pressure. The stock is near its 52-week low after Piper Sandler cut its price target to $80.00 on August 11, 2026. Despite strong profitability with a net margin of 27.69% and ROE of 64.91%, Q2 2026 revenue missed estimates, and the company reduced its 2026 outlook due to softer pet healthcare demand. Cash flow improved in 2025 with net cash flow of $325 million, but debt-to-asset ratio remains elevated at 46.14%.
The outlook is cautious with near-term headwinds in companion animal markets, but long-term fundamentals remain solid given the company's leading position in animal health. Risks include competitive pressures and a class action lawsuit. Analyst consensus is a Buy with a $95.00 price target, implying significant upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
